Compare Monolithic Power Systems Inc (MPWR) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Monolithic Power Systems Inc trades at $1,238 (market cap $64.85B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Monolithic Power Systems Inc is far larger — about 13.3× Travere Therapeutics Inc. Common Stock's market cap, and Monolithic Power Systems Inc pays a 0.61% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Monolithic Power Systems Inc for 25 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MPWR | TVTX | |
|---|---|---|
Market Cap | $64.85B | $4.88B |
Volume | 692,538 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $1.69K | $67.52 |
52-Week Low | $856.96 | $26.79 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $63.45B | $5.01B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPWR trades at $1,319.55 with minimal daily movement (+0.02%) amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, 24.5% net margins, and robust revenue growth from $2.8B to $3.3B year-over-year. Recent news highlights CEO share sales and a manufacturing partnership with GlobalFoundries to support AI and data center demand. Valuation remains elevated with P/E at 80.5 and P/S at 19.7, reflecting high growth expectations.
The outlook remains positive given analyst consensus (88% buy ratings) and a $1,830 price target, but risks include premium valuation compression, insider selling, and dependence on AI infrastructure growth. Cash flow strength supports dividend payments, though technical weakness near key support at $1,300 requires monitoring for sustained bullish momentum.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
